WTAP-mediated m6A modification of IFNE is required for antiviral defense in condyloma acuminata

Gu, Zhichao; Liu, Jiaying; Qin, Lei; Zhang, Yong; Cui, Wenjin; Huang, Huayu; Lian, Ling; Cao, Yu; Zhang, Huafeng

doi:10.1016/j.jdermsci.2023.07.004

Cited by 4 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, it was reported that HR-HPV 16/18 infection in cervical cancer stabilized m6A-methylated MYC expression by regulating IGF2BP2, an m6A reader, further promoting aerobic glycolysis ( Hu et al, 2022 ). Increased m6A modification of interferon- ϵ dependent on WT1-associated protein was revealed to mediate the antiviral response in CA ( Gu et al, 2023 ). However, there are still very few data on transcriptome m6A changes and their probable functions and regulatory mechanisms in the pathogenesis of CA.…”

Section: Introdutionmentioning

confidence: 99%

Alteration of RNA m6A methylation mediates aberrant RNA binding protein expression and alternative splicing in condyloma acuminatum

Liu,

Xie,

Wang

et al. 2024

PeerJ

View full text Add to dashboard Cite

Background Condyloma acuminatum (CA) is caused by low-risk human papillomavirus, and is characterized by high recurrence after treatment. The RNA modification N6-methyladenosine (m6A) plays an important role during diverse viral infections, including high-risk HPV infection in cervical cancer. However, it is unclear whether low-risk HPV infection changes the RNA m6A methylation in CA. Methods High-throughputm6A-sequencing was performed to profile the transcriptome-wide mRNA modifications of CA tissues infected by LR-HPVs and the paired normal tissues from CA patients. We further investigated the regulation of alternative splicing by RNA binding proteins (RBPs) with altered m6A modification and constructed a regulatory network among these RBPs, regulated alternative splicing events (RASEs) and regulated alternative splicing genes (RASGs) in CA. Results The results show that the m6A level in CA tissues differed from that in the paired controls. Furthermore, cell cycle- and cell adhesion- associated genes with m6A modification were differentially expressed in CA tissues compared to the paired controls. In particular, seven RNA binding protein genes with specific m6A methylated sites, showed a higher or lower expression at the mRNA level in CA tissues than in the paired normal tissues. In addition, these differentially expressed RNA binding protein genes would regulate the alternative splicing pattern of apoptotic process genes in CA tissue. Conclusions Our study reveals a sophisticated m6A modification profile in CA tissue that affects the response of host cells to HPV infection, and provides cues for the further exploration of the roles of m6A and the development of a novel treatment strategy for CA.

show abstract

Section: Introdutionmentioning

confidence: 99%

Alteration of RNA m6A methylation mediates aberrant RNA binding protein expression and alternative splicing in condyloma acuminatum

Liu,

Xie,

Wang

et al. 2024

PeerJ

View full text Add to dashboard Cite

show abstract

Role of N6‐methyladenosine RNA modification in cancer

Qu,

Gao,

Zhang

et al. 2024

MedComm

View full text Add to dashboard Cite

N6‐methyladenosine (m6A) is the most abundant modification of RNA in eukaryotic cells. Previous studies have shown that m6A is pivotal in diverse diseases especially cancer. m6A corelates with the initiation, progression, resistance, invasion, and metastasis of cancer. However, despite these insights, a comprehensive understanding of its specific roles and mechanisms within the complex landscape of cancer is still elusive. This review begins by outlining the key regulatory proteins of m6A modification and their posttranslational modifications (PTMs), as well as the role in chromatin accessibility and transcriptional activity within cancer cells. Additionally, it highlights that m6A modifications impact cancer progression by modulating programmed cell death mechanisms and affecting the tumor microenvironment through various cancer‐associated immune cells. Furthermore, the review discusses how microorganisms can induce enduring epigenetic changes and oncogenic effect in microorganism‐associated cancers by altering m6A modifications. Last, it delves into the role of m6A modification in cancer immunotherapy, encompassing RNA therapy, immune checkpoint blockade, cytokine therapy, adoptive cell transfer therapy, and direct targeting of m6A regulators. Overall, this review clarifies the multifaceted role of m6A modification in cancer and explores targeted therapies aimed at manipulating m6A modification, aiming to advance cancer research and improve patient outcomes.

show abstract

Emerging role of N6-methyladenosine RNA modification in regulation of SARS-CoV-2 infection and virus-host interactions

Liu,

Chen,

Guo

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

WTAP-mediated m6A modification of IFNE is required for antiviral defense in condyloma acuminata

Cited by 4 publications

References 31 publications

Alteration of RNA m6A methylation mediates aberrant RNA binding protein expression and alternative splicing in condyloma acuminatum

Alteration of RNA m6A methylation mediates aberrant RNA binding protein expression and alternative splicing in condyloma acuminatum

Role of N6‐methyladenosine RNA modification in cancer

Emerging role of N6-methyladenosine RNA modification in regulation of SARS-CoV-2 infection and virus-host interactions

Contact Info

Product

Resources

About